Webinar: Introducing the Breath Biopsy® Microbiome Panel: using breath as a non-invasive tool to study the microbiome
Online, 24 Jul 2025
We are looking forward to our next webinar in July 2025. Join this online event to learn about the Breath Biopsy® Microbiome Panel, offering precise quantification of key metabolites in exhaled breath originating from the gut microbiome.
Dr Huw Davies, VP of Business Development, Research Products and Services, will be joined by Dr Nabeeth Nagalingam, Principal Translational Scientist on 24th July for the webinar at 3 – 3:45pm BST, (4 – 4:45pm CEST, 10 – 10:45am EDT, 7 – 7:45am PDT).
‘Introducing the Breath Biopsy® Microbiome Panel: using breath as a non-invasive tool to study the microbiome’
Join us as we introduce the Breath Biopsy® Microbiome Panel, a non-invasive tool for studying gut microbiome activity through exhaled breath.
Ideal for researchers investigating known microbiome metabolites or exploring new health and disease links, this webinar will explore how breath anaylsis offers unique advantages including:
- Analyse system-wide microbial metabolites absorbed in thie blood stream
- Enables real-time monitoring of metabolites produced during digestion and fermentation
- Improved subject recruitment and retention due to the non-invasive nature of sample collection
Sign up today to join the webinar and partcipate in the live Q&A after the webinar. If you cannot make it, be sure to still sign up to receive the recording straight to your email.
Learn more about our Speakers:
Dr Huw Davies
Dr Huw Davies has over 30 years experience working with novel technologies that enable the diagnosis and treatment of major human diseases. In his current role, Huw leads a global commercial team responsible for growing Owlstone Medical’s Breath Biopsy® collaborations and service business with leading pharmaceutical companies and academic partners to identify and deploy novel non-invasive breath biomarkers for precision medicine and disease diagnosis.
Dr Nabeetha Nagalingam
Dr. Nabeetha Nagalingam is a Principal Translational Scientist with over a decade of experience in microbiome research, biomarker discovery, and test development.
Based at Owlstone Medical in Cambridge, UK, she provides scientific leadership on gut health, infectious diseases and microbiome initiatives, driving innovation across early-stage research and external collaborations. She offers insight and technical expertise in the design, execution, and evaluation of translational research and biomarker development programs.